Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis

Clinical Immunology

Volumn 147, Issue 2, 2013, Pages 105-119

  Ayers, Chris L ^a,b   Mendoza, Jason P ^a,c   Sinha, Sushmita ^a   Cunnusamy, Khrishen ^a   Greenberg, Benjamin M ^a   Frohman, Elliot M ^a   Karandikar, Nitin J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Opexa Therapeutics Inc   (United States)

^c Teva Pharmaceuticals   (United States)

Author keywords

Glatiramer acetate; Immunomodulation; Multiple sclerosis

Indexed keywords

GLATIRAMER; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MALE; MIXED LYMPHOCYTE REACTION; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84876337179     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.02.015     Document Type: Article

References (33)

1. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 1998, 92:113-121.
2. Brenner T., Arnon R., Sela M., Abramsky O., Meiner Z., Riven-Kreitman R., Tarcik N., Teitelbaum D. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J. Neuroimmunol. 2001, 115:152-160.
3. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., Hafler D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 2000, 105:967-976.
4. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then Bergh F., Dose T., Wekerle H., Hohlfeld R. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:7452-7457.
5. Qin Y., Zhang D.Q., Prat A., Pouly S., Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J. Neuroimmunol. 2000, 108:201-206.
6. Hong J., Li N., Zhang X., Zheng B., Zhang J.Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:6449-6454.
7. Karandikar N.J., Crawford M.P., Yan X., Ratts R.B., Brenchley J.M., Ambrozak D.R., Lovett-Racke A.E., Frohman E.M., Stastny P., Douek D.C., Koup R.A., Racke M.K. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. 2002, 109:641-649.
8. Biegler B.W., Yan S.X., Ortega S.B., Tennakoon D.K., Racke M.K., Karandikar N.J. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J. Neuroimmunol. 2006, 180:159-171.
9. Tennakoon D.K., Mehta R.S., Ortega S.B., Bhoj V., Racke M.K., Karandikar N.J. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J. Immunol. 2006, 176:7119-7129.
10. Ratts R.B., Lovett-Racke A.E., Choy J., Northrop S.C., Hussain R.Z., Karandikar N.J., Racke M.K. CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate. J. Neuroimmunol. 2006, 178:117-129.
11. Weber M.S., Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., Patarroyo J.C., Stuve O., Sobel R.A., Steinman L., Zamvil S.S. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 2007, 13:935-943.
12. Begum-Haque S., Sharma A., Christy M., Lentini T., Ochoa-Reparaz J., Fayed I.F., Mielcarz D., Haque A., Kasper L.H. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 219:47-53.
13. Kala M., Rhodes S.N., Piao W.H., Shi F.D., Campagnolo D.I., Vollmer T.L. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp. Neurol. 2010, 221:136-145.
14. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., Stastny P., Douek D.C., Koup R.A., Racke M.K., Karandikar N.J. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103:4222-4231.
15. Baughman E.J., Mendoza J.P., Ortega S.B., Ayers C.L., Greenberg B.M., Frohman E.M., Karandikar N.J. Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J. Autoimmun. 2011, 36:115-124.
16. Pillai V., Ortega S.B., Wang C.K., Karandikar N.J. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin. Immunol. 2007, 123:18-29.
17. Ayers C.L., Firan M., Pillai V., Lee W.M., Karandikar N.J. Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection. Viral Immunol. 2011, 24:119-129.
18. Walker M.R., Carson B.D., Nepom G.T., Ziegler S.F., Buckner J.H. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4103-4108.
19. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., Ziegler S.F. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 2003, 112:1437-1443.
20. Kim H.J., Ifergan I., Antel J.P., Seguin R., Duddy M., Lapierre Y., Jalili F., Bar-Or A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol. 2004, 172:7144-7153.
21. Weber M.S., Starck M., Wagenpfeil S., Meinl E., Hohlfeld R., Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004, 127:1370-1378.
22. Michalowska-Wender G., Losy J., Wender M., Januszkiewicz-Lewandowska D., Nowak J. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers. Pol. J. Pharmacol. 2003, 55:877-880.
23. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
24. Venken K., Hellings N., Thewissen M., Somers V., Hensen K., Rummens J.L., Medaer R., Hupperts R., Stinissen P. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008, 123:79-89.
25. Haas J., Hug A., Viehover A., Fritzsching B., Falk C.S., Filser A., Vetter T., Milkova L., Korporal M., Fritz B., Storch-Hagenlocher B., Krammer P.H., Suri-Payer E., Wildemann B. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 2005, 35:3343-3352.
26. Schneider A., Rieck M., Sanda S., Pihoker C., Greenbaum C., Buckner J.H. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 2008, 181:7350-7355.
27. Venigalla R.K., Tretter T., Krienke S., Max R., Eckstein V., Blank N., Fiehn C., Ho A.D., Lorenz H.M. Reduced CD4+, CD25- T cell sensitivity to the suppressive function of CD4+, CD25high, CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 2008, 58:2120-2130.
28. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., Backstrom B.T., Sobel R.A., Wucherpfennig K.W., Strom T.B., Oukka M., Kuchroo V.K. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 2007, 13:423-431.
29. Yang J., Brook M.O., Carvalho-Gaspar M., Zhang J., Ramon H.E., Sayegh M.H., Wood K.J., Turka L.A., Jones N.D. Allograft rejection mediated by memory T cells is resistant to regulation. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19954-19959.
30. Vieira P.L., Heystek H.C., Wormmeester J., Wierenga E.A., Kapsenberg M.L. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 2003, 170:4483-4488.
31. Jung S., Siglienti I., Grauer O., Magnus T., Scarlato G., Toyka K. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J. Neuroimmunol. 2004, 148:63-73.
32. Burger D., Molnarfi N., Weber M.S., Brandt K.J., Benkhoucha M., Gruaz L., Chofflon M., Zamvil S.S., Lalive P.H. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4355-4359.
33. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 2008, 5:45-57.